New nano drug aims to combat wasting in pancreatic cancer patients
NCT ID NCT07408505
First seen Feb 14, 2026 · Last updated May 24, 2026 · Updated 13 times
Summary
This study tests a new nano-formulation of megestrol acetate in 56 patients with advanced pancreatic cancer who suffer from anorexia-cachexia syndrome, a condition causing severe appetite loss and weight loss. The goal is to see if the drug can help patients gain weight, improve appetite, and enhance quality of life during their cancer treatment. Participants will be randomly assigned to receive either the nano-drug or a placebo alongside their standard cancer therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jinan, Shandong 0531
RECRUITINGJinan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.